Assessment of the state of intestinal microbiocenosis based on bacterial endotoxin and plasmalogen in elderly persons with type 2 diabetes mellitus pathology

2021 ◽  
Vol 66 (9) ◽  
pp. 565-570
Author(s):  
S. L. Bezrodny ◽  
S. G. Mardanly ◽  
A. M. Zatevalov ◽  
E. V. Tereshina ◽  
A. Yu. Mironov ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly People ◽  
Roc Analysis ◽  
Plasma Concentrations ◽  
The State ◽  
Elderly Persons ◽  
Intestinal Microbiocenosis

The concentration of bacterial plasmalogen 18a and endotoxin in the blood of elderly people 45-90 years old with the pathology of type 2 diabetes mellitus (DM 2) - the main group and without diabetes mellitus - the comparison group was investigated. The concentration of both plasmalogen 18a and endotoxin in the blood of individuals with DM 2 pathology is statistically significantly higher than in the blood of individuals without DM 2 pathology. To assess the state of microbiocenosis and predict type 2 diabetes mellitus, decisive rules have been determined in the form of threshold values of plasma concentrations 18a and endotoxin in the blood of elderly people with a suspected or established diagnosis of type 2 diabetes. Using ROC analysis, it was found that values above 20.66 μg / ml for plasmalogen 18a, and 0.48 nmol / ml for endotoxin, determine the presence of type 2 diabetes mellitus pathology in the 45-90 age group.

scholarly journals Survey of Hypoglycemia in Elderly People With Type 2 Diabetes Mellitus in Japan

2015 ◽  
Vol 7 (12) ◽  
pp. 967-978 ◽  
Author(s):  
Masahiro Fukuda ◽  
Kunihiro Doi ◽  
Masahiro Sugawara ◽  
Yoshikazu Naka ◽  
Kouichi Mochizuki
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly People

scholarly journals Risk factors for dementia with type 2 diabetes mellitus among elderly people in China

2013 ◽  
Vol 42 (3) ◽  
pp. 398-400 ◽  
Author(s):  
M. Fei ◽  
Z. Yan Ping ◽  
M. Ru Juan ◽  
L. Ning Ning ◽  
G. Lin
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly People

scholarly journals Once daily versus twice daily Linagliptin effect on glycemic levels in type 2 diabetes mellitus- an observational study

2017 ◽  
Vol 5 (10) ◽  
pp. 4403
Author(s):  
Riyaz Mohammed ◽  
Mohammed Azfar Ali
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Observational Study ◽  
Plasma Concentrations ◽  
Fixed Dose ◽  
Once Daily ◽  
Group A ◽  
Group B

Background: DPP-4 is widely distributed in endothelial cells, pancreas, uterus, liver, salivary glands, lymph node, spleen, and thymus. DPP-4 regulates glucagon-like peptide (GLP)-1, and glucose-dependent insulin tropic peptide (GIP) which leads to glucose homeostasis via enhancing insulin secretion and suppression of glucagon, which results in control of post-prandial and fasting hyperglycemia.Methods: These 40 patients who were enrolled as per the inclusion criteria of receiving metformin dosage of 2 gram per day in established type 2 diabetes mellitus patients with no comorbidities. these patients were divided randomly into two groups comprising of 20 patients each, group A received linagliptin 5 mg per day in addition to metformin 1gm twice daily whereas group B received linagliptin 5 mg per day in a fixed dose (Linagliptin + metformin) of 2.5/1000 twice daily.Results: In the present observational study, the mean age in group A was 46.7±9.4 compared to 51.65±9.9 in group B, p >0.05, mean BMI in group A was 27.8±1.1 compared to 27.28±0.93 in group B p >0.05, Mean FBS in group A was 157.9±24.1 compared to 146.2±21.8 in group B p >0.05, Mean PPBS in group A was 245.8±32.7 compared to 246.2±39.3 in group B p >0.05 and Mean HbA1c in group A was 7.67±0.58 compared to 7.6±0.5 in group B p >0.05. Group A patients were initiated on once daily linagliptin, there was a significant reduction in FBS, PPBS and HbA1c at the end of 6 months p <0.001. Similarly, Group B patients who were initiated on twice daily linagliptin also showed a significant reduction in FBS, PPBS and HbA1c at the end of 6 months p <0.001.Conclusions: The addition of linagliptin to metformin treatment was effective and well tolerated in patients with type 2 diabetes. Linagliptin add-on to metformin during the early course of treatment helps in delaying the exhaustion of pancreatic islet function. Plasma concentrations of linagliptin decline in at least a biphasic manner with a long terminal half-life (>100 hours), related to the saturable binding of linagliptin to DPP-4. The prolonged elimination phase does not contribute to the accumulation of the drug. Addition of linagliptin to metformin has shown a significant reduction in FBS, PPBS and HbA1c.

Sign in / Sign up

Export Citation Format

Share Document